IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience clinical drug development, today announces that it is scheduled to attend and present scientific posters at the 2019 Clinical Trials on Alzheimer’s Disease (CTAD) Congress held from 4th-7th December 2019 in San Diego, California, USA. CTAD Congress 2019 4th – 7th December […]
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, will announce its final results for the year ended 30 September 2019 on Wednesday, 4 December 2019. Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 GMT on the day of the results. […]
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces three new biopharma contracts and the appointment of Lammert Albers as Chief Business Officer effective immediately. The new contracts are: · A start up agreement with a new client for a new multi-study programme in Progressive Supranuclear Palsy (PSP), with […]
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, is pleased to announce a trading update for the year ended 30 September 2019. IXICO is expecting its first full year of positive earnings before interest, tax, depreciation and amortisation (“EBITDA”) since listing. This better than forecast performance has been driven by […]
